Attached files
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
In connection with the Amendment No. 1 on Form
10-K/A to the Annual Report of Tenax
Therapeutics, Inc. (the
“Company”) on Form 10-K for the year ended December 31,
2020 as filed with the Securities and Exchange Commission on the
March 31, 2021 (the “Report”), I, Anthony DiTonno,
Chief Executive Officer (Principal Executive Officer) of the
Company, certify pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:
(1)
the Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
and
(2)
the information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
|
Date: April 16, 2021
|
|
/s/ Anthony DiTonno
|
|
|
|
|
Anthony
DiTonno
|
|
|
|
|
Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
|
|
|
The foregoing certification is being furnished solely to
accompany the Report pursuant to 18 U.S.C. Section 1350 and is
not being filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by
reference into any filing of the Company, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.
A signed original of this written statement required by Section 906
of the Sarbanes-Oxley Act of 2002 has been provided to the Company
and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request.